(BUSINESS WIRE)--Aug. 2, 2000--PA Consulting Group has supported the first ever simultaneous NASDAQ/AIM listing of a biotechnology company. Israeli biotechnology company Keryx Biopharmaceuticals, Inc. announced today it has successfully gained admission to both stock markets and raised $46 million.
PA provided third party due diligence on the technological aspects, explaining the science in language that investors can understand. PA's Independent Experts' Report is included in the 'harmonized' issue document, designed to meet both US and UK listing requirements. The inclusion of such third party due diligence in an offer document is unique for an initial offering on the US stock market, although commonplace in London and European equity market offerings....
Keryx Biopharmaceuticals, Inc. is an Israeli biotechnology company registered in Delaware, US, which generates drug candidates targeting protein kinases using data discovered through the mapping of the human genome. Its KinAce platform has produced 13 lead compounds in less than two years, eight of which have already produced positive results through in vivo tests. In addition to developing drug candidates with its KinAce platform, Keryx has obtained a license for sulodexide and is developing this drug for the treatment of diabetic nephropathy.
Aug. 2 /CNW/ -- AltaRex Corp. (Toronto: AXO, OTC: ALRXF), a developer of antibody-based cancer therapeutics, announced today that it has filed a final prospectus with the Ontario Securities Commission to raise up to C$7.8 million through the sale of Common Shares at C$0.85 per share. This offering is expected to close on August 9, 2000 and will support the continuing clinical development of OvaRex(TM) MAb. |
